Akademik Veri Yönetim Sistemi
Comprehensive medicine, cilt.15, sa.1, ss.39-43, 2023 (TRDizin)
Objective: Patients with diagnosis of chronic obstructive pulmonary disease (COPD) in the intensive care unit have high mortality rate between 14% and 41%. Therefore, markers to predict mortality and morbidity in the early period of intensive care hospitalization are important for these patients. In this study, we aimed to evaluate the biochemical markers in predicting mortality, morbidity, and possible complications in the intensive care follow-up of patients with COPD diagnosis. Materials and Methods: Demographic data, laboratory results, treatments, complications, length of stay, mortality, and morbidity of COPD patients treated in intensive care unit between January 2012 and January 2019 were recorded. To assess the sensitivity of C-reactive protein, procalcitonin, white blood cells, and lactate in predicting mortality and complications, patients were divided into two main groups as “deceased” and “discharge.” Results: In this study, the “procalcitonin 1st day” values of the “exitus” patient group were higher than the “discharged” group (p<0.01). Between “Procalcitonin 1st day” and “COPD stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria,” the relationship was statistically significant (p<0.05). Procalcitonin measured on admission day to intensive care unit of patients who are later discharged with tracheostomies were found to be statistically significantly higher. Conclusion: In this study, procalcitonin was found to be the most valuable biomarker in predicting mortality and morbidity. Procalcitonin levels measured on the day of hospitalization were found to be statistically associated with COPD stages according to GOLD criteria. Therefore, we think that for those kinds of patients, procalcitonin may be used as an early predictor of bad prognosis.